Research programme: 4-1BB receptor agonists - Apogenix

Drug Profile

Research programme: 4-1BB receptor agonists - Apogenix

Alternative Names: CD137 agonists - Apogenix; HERA-CD137L

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apogenix
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action CD137 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 Sep 2017 Preclinical data in Solid tumours presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)
  • 15 Dec 2015 Research programme: 4-1BB agonists - Apogenix is available for licensing as of 15 Dec 2015. www.apogenix.com
  • 15 Dec 2015 Preclinical trials in Solid tumours in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top